Prostate Cancer Clinical Trials in Madison, Wisconsin

13 studies are recruiting for prostate cancer in Madison, Wisconsin right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

   Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University Hospital and UW Health Clinics ( Site 0065), Madison, Wisconsin

   Locations

   298 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06925737 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

   The purpose of this study is to find out if giving radiation therapy (RT) to areas of metastatic prostate cancer at the time a participant is diagnosed will help control disease better than the usual treatment. This treatment is called metastasis-directed radiotherapy (MDRT). The usual treatment fo…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Carbone Cancer Center University of Wisconsin-Madison, Madison, Wisconsin

   Locations

   3 in total

   Run by

   Case Comprehensive Cancer Center

   See if you can join NCT06150417 on ClinicalTrials.gov

4. Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

   The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Wisconsin, Madison, Wisconsin

   Locations

   34 in total

   Run by

   Clarity Pharmaceuticals Ltd

   See if you can join NCT06056830 on ClinicalTrials.gov

5. A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

   Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UW Health Carbone Cancer Center, Madison, Wisconsin

   Locations

   54 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT07005154 on ClinicalTrials.gov

6. PET/CT Characterization of Treatment Resistance

   This study will use different types of medical imaging to assess how lesions from advanced prostate cancer become resistant to second-generation AR-targeted therapy, and how the different types of imaging compare in that assessment. Participants in this study have advanced prostate cancer and are e…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Wisconsin, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT05647564 on ClinicalTrials.gov

7. COMPASS Study for Metastatic Castration-resistant Prostate Cancer

   This study is a companion to the SYNERGY-201 clinical trial (NCT06228053), which investigates SX-682 and enzalutamide in individuals with prostate cancer. Individuals must be participating in SYNERGY-201 in order to participate in this study. The purpose of this companion study is to learn more abo…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

   Locations

   4 in total

   Run by

   Duke University

   See if you can join NCT07050433 on ClinicalTrials.gov

8. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Wisconsin, Carbone Cancer Center, Madison, Wisconsin

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

9. This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

   This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin

   Locations

   337 in total

   Run by

   Pfizer

   See if you can join NCT07028853 on ClinicalTrials.gov

10. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

    Stage

    Phase 1

    Ages

    18 to 100

    Site

    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

    Locations

    36 in total

    Run by

    Janux Therapeutics

    See if you can join NCT05519449 on ClinicalTrials.gov

11. International Registry for Men With Advanced Prostate Cancer (IRONMAN)

    Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry an…

    Stage

    Not phased

    Ages

    21 and older

    Site

    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

    Locations

    121 in total

    Run by

    Prostate Cancer Clinical Trials Consortium

    See if you can join NCT03151629 on ClinicalTrials.gov

12. Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

    This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic pros…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin

    Locations

    20 in total

    Run by

    VA Office of Research and Development

    See if you can join NCT04787744 on ClinicalTrials.gov

13. ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials

    This study will follow men with metastatic castration resistant prostate cancer throughout their standard of care treatment for their disease to determine if the presence of different genes or proteins can predict which patients respond to the cancer treatment they receive. As tumors grow and begin…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Wisconsin-Madison, Madison, Wisconsin

    Locations

    3 in total

    Run by

    Duke University

    See if you can join NCT06141993 on ClinicalTrials.gov